Welcome to our dedicated page for Ideaya Biosciences SEC filings (Ticker: IDYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IDEAYA Biosciences, Inc. filings document the regulatory record of a Nasdaq-listed precision oncology company developing targeted therapeutics and biomarker-directed cancer programs. Recent 8-K reports cover financial results, business updates, clinical data from the OptimUM darovasertib program, collaboration agreements involving investigational oncology assets, and Regulation FD corporate presentations.
The company’s SEC record also includes proxy materials for annual meeting governance, executive compensation and equity-plan matters. Registration and prospectus filings describe IDEAYA’s common stock, automatic shelf registration capacity, at-the-market sales arrangements and related capital-structure disclosures, alongside risk and pipeline information tied to its clinical-stage oncology portfolio.
Ideaya Biosciences, Inc. — Janus Henderson Group plc reports beneficial ownership of 7,265,253 shares of Ideaya common stock, representing 8.3% of the class as reported on 03/31/2026. The holdings are exercised through multiple Asset Managers with shared voting and shared dispositive power over these shares on behalf of managed client accounts; the filing notes the Asset Managers disclaim rights to receive dividends or sale proceeds associated with that ownership interest.
IDEAYA Biosciences, Inc. filed a new automatic shelf registration statement on Form S-3ASR and an at-the-market prospectus supplement that together cover potential common stock sales with aggregate gross proceeds of up to $156.6 million under its existing Open Market Sales Agreement with Jefferies LLC.
The new shelf replaces a prior automatic shelf that would have expired in June 2026, which is deemed terminated as of the new statement’s effective date. IDEAYA has previously sold common stock with an aggregate gross sales price of $193,447,003.19 under this agreement, and the remaining capacity is now available for discretionary future sales.
IDEAYA Biosciences filed a prospectus supplement for an at-the-market offering under a shelf registration that permits up to $350,000,000 aggregate sales of common stock through Jefferies LLC as sales agent. The supplement states $193,447,003.19 of that capacity has been sold previously and $156,552,996.81 remains available for sale under the January 19, 2024 sales agreement. Sales will be made on Nasdaq as “at the market offerings” and Jefferies may receive up to 3.0% of gross proceeds as compensation. The filing discloses 87,856,154 shares outstanding as of March 31, 2026 and a last reported sales price of $28.19 per share on May 1, 2026. The company intends to use net proceeds for general corporate purposes, including working capital and clinical development.
IDEAYA Biosciences filed an automatic shelf registration statement to offer Common Stock, Preferred Stock, Debt Securities, Warrants and Units from time to time after the effective date. The shelf prospectus allows multiple offering methods (underwriters, dealers, agents or direct sales) and states that specific terms, amounts and use of proceeds will be provided in prospectus supplements.
The prospectus notes the company’s Nasdaq listing and a reported last sale price of $28.19 per share for Common Stock on May 1, 2026, and incorporates by reference ongoing Exchange Act filings for risk factors and financial details.
IDEAYA Biosciences reported first-quarter 2026 results showing collaboration revenue of $6.6 million, driven by its darovasertib license with Servier. Operating expenses rose as research and development reached $95.7 million and general and administrative costs were $19.4 million, leading to a net loss of $98.5 million and a net loss per share of $1.11.
Despite the loss, IDEAYA ended the quarter with strong liquidity, holding cash, cash equivalents and marketable securities totaling about $972.9 million. Management believes this balance will fund planned operations for at least 12 months while advancing a nine-candidate oncology pipeline, including multiple Phase 2/3 trials for darovasertib in uveal melanoma.
IDEAYA Biosciences reported a larger net loss for the first quarter of 2026 while highlighting major progress in its oncology pipeline. The company posted a net loss of $98.5 million, compared with $83.3 million in the prior quarter, on collaboration revenue of $6.6 million.
Cash, cash equivalents and marketable securities totaled $972.9 million as of March 31, 2026, and IDEAYA reiterated cash runway guidance into 2030. Research and development expenses rose to $95.7 million, reflecting increased clinical activity, while general and administrative costs were $19.4 million.
The company reported that its Phase 2/3 registrational trial of darovasertib plus crizotinib in first-line HLA*A2-negative metastatic uveal melanoma met its primary endpoint, reducing the risk of disease progression by 58% with median progression-free survival of 6.9 months versus 3.1 months for investigator choice of therapy. IDEAYA plans a new drug application in the second half of 2026 under the FDA’s Real-Time Oncology Review program and outlined multiple additional clinical milestones across its ADC and synthetic lethality portfolio through 2026 and 2027.
IDEAYA Biosciences, Inc. is soliciting proxies for its 2026 virtual annual meeting on June 16, 2026 at 1:30 p.m. Pacific Time. Stockholders will vote to elect three Class I directors until the 2029 meeting, ratify PricewaterhouseCoopers LLP as independent auditor for 2026, and approve a non-binding advisory say-on-pay resolution.
Holders of 87,860,920 shares of common stock as of April 20, 2026 may vote online, by phone or by mail. The board recommends voting FOR all three proposals.
IDEAYA Biosciences reported strong positive Phase 2/3 data for darovasertib plus crizotinib in first-line metastatic uveal melanoma. In 313 patients, the combination cut the risk of disease progression by 58% versus investigator’s choice therapy, with a hazard ratio of 0.42 and p<0.0001.
Median progression-free survival was 6.9 months on the combination versus 3.1 months on standard regimens, and overall response rate was 37.1% versus 5.8%. Five complete responses were seen on the combination and none in the control arm. Safety was generally manageable, and IDEAYA plans to submit a U.S. NDA in the second half of 2026.
IDEAYA Biosciences entered a clinical collaboration with AstraZeneca to test IDEAYA’s investigational DLL3 TOP1 antibody-drug conjugate IDE849 together with AstraZeneca’s PD-L1 inhibitor Imfinzi in extensive-stage small cell lung cancer.
IDEAYA will sponsor the combination study, while AstraZeneca supplies Imfinzi. IDEAYA is running a multi-site global Phase 1 clinical trial of IDE849 in DLL3 upregulated solid tumors, including small cell lung cancer, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma, reflecting significant unmet medical need and the potential of DLL3 as a targeted therapy approach.